arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

CASI Pharmaceuticals, Inc.

CASIF

— Price unavailable

7 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Moderately Bearish

auto_awesome

Analytical Summary

CASI Pharmaceuticals, Inc. faces fundamental challenges. On the positive side, Return on Common Equity (%) remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap —

Dividend Yield —

Revenue Growth -27.4% ↘

Op. Margin -217.3% ↘

ROIC 95.4% ↗

FCF / Share $-1.12 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$20.71M

↓ -27.4% —

Net Income Profit after all expenses

$-48.06M

↓ -22.4% —

Operating Margin Operating profit as % of sales

-217.3%

↓ -56.5% 0th

FCF / Share Free cash flow per share

$-1.12

↑ +41.6% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓

Returns

100

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Revenue Growth YoY (%)	-27.4% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-443%)	-15.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-297%)	-21.4% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-368%)	42.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+436%)	99.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1141%)	—	—
EPS Growth YoY (%)	-1.2% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-26.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	32.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-11.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	38.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-22.4% Weak ↓ Weak Declining Year-over-year change in net income	-45.6% Weak ↓ Weak Declining Year-over-year change in net income	34.3% Excellent ↑ Excellent Improving Year-over-year change in net income	-11.9% Weak Weak Year-over-year change in net income	24.1% Good Good Year-over-year change in net income	—	—
FCF Growth YoY (%)	41.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-27.1% Weak ↓ Weak Declining Year-over-year change in free cash flow	22.8% Good ↑ Good Improving Year-over-year change in free cash flow	25.6% Excellent Excellent Year-over-year change in free cash flow	-6.1% Weak Weak Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	-21.7% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-1.8% Weak Weak Compound annual revenue growth over 3 years	30.8% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	6.5% Fair Fair Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Operating Margin (%) (%)	-217.3% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1549%)	-138.8% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1026%)	-74.0% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-594%)	-78.9% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-626%)	-137.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1017%)	-348.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2424%)	—
Profit Margin (%) (%)	-232.0% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2034%)	-137.6% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1246%)	-79.6% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-763%)	-95.1% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-893%)	-121.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1112%)	-318.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2758%)	—
FCF Margin (%) (%)	-100.3% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-103.2% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-59.5% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-61.9% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-118.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-180.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.43x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.65x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.57x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Return on Invested Capital (%)	95.4% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-1691.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-46.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-60.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-38.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-51.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-175.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-73.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-33.3% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-35.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-30.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	128.9% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+759%)	—	-111.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-844%)	-92.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-713%)	-43.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-389%)	-59.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-495%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Debt to Equity (x)	—	—	0.78x Fair Fair Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+30%)	—	—	—	—
Interest Coverage (x)	-11251.75x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	-14315.86x Weak Weak Operating income divided by interest expense Optimal: > 5x	-17026.13x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-5.63M	$-13.47M	$1.81M	$-47.11M	$-38.70M	—	—
Debt / EBITDA (x)	—	—	-0.84x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Revenue per Share (USD)	$1.12	$1.86	$2.54	$3.16	$2.22	$1.37	—
Basic EPS, GAAP (USD)	$-2.59	$-2.56	$-2.02	$-3.01	$-2.69	$-4.37	—
Free Cash Flow per Share (USD)	$-1.12	$-1.92	$-1.51	$-1.96	$-2.63	$-2.48	—
Book Value per Share (USD)	$-1.81	$0.12	$1.81	$3.31	$6.04	$7.38	—
Tangible Book Value per Share (USD)	$-1.82	$0.10	$1.67	$3.23	$5.17	$7.38	—
Basic Weighted Avg Shares (shares)	18.54M	15.34M	13.36M	13.65M	13.61M	11.05M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Working Capital (USD)	$-36.21M	$3.12M	$42.62M	$56.42M	$48.78M	—	—
LT Debt (USD)	—	—	$18.89M	—	—	—	—
Total Equity (USD)	$-37.28M	$1.85M	$24.16M	$44.57M	$84.50M	$81.54M	$73.00M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Sales/Revenue/Turnover (USD)	$20.71M	$28.54M	$33.88M	$43.11M	$30.17M	$15.14M	—
Depreciation Expense (USD)	$1.20M	$1.30M	$2.50M	$1.20M	$500.00K	$600.00K	—
Net Income, GAAP (USD)	$-48.06M	$-39.26M	$-26.96M	$-41.01M	$-36.65M	$-48.29M	—
Operating Cash Flow (USD)	$-20.75M	$-29.22M	$-19.97M	$-21.09M	$-26.84M	$-25.89M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 7 quarters

CASI Pharmaceuticals, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CASIF with peers